Clinical Pharmacokinetics and Potentially Important Drug Interactions of Sulphinpyrazone

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1982 Jan 1

PMID 7042172

Citations 4

Authors

A K Pedersen

P Jakobsen

J P Kampmann

J M Hansen

Affiliations

Soon will be listed here.

Citing Articles

Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study.

Kuo B, Ritschel W Pharm Res. 2013; 3(3):178-83.

PMID: 24271526 DOI: 10.1023/A:1016322326443.

A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?.

Lee M, Graham G, Williams K, Day R Drug Saf. 2008; 31(8):643-65.

PMID: 18636784 DOI: 10.2165/00002018-200831080-00002.

Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.

Rosenkranz B, Fischer C, Jakobsen P, Kirstein Pedersen A, Frolich J Eur J Clin Pharmacol. 1983; 24(2):231-5.

PMID: 6840173 DOI: 10.1007/BF00613823.

Renal clearance of sulphinpyrazone in man.

Lentjes E, Russel F, van Ginneken C Eur J Clin Pharmacol. 1986; 31(4):473-8.

PMID: 3816927 DOI: 10.1007/BF00613527.

References

Lecaillon J, Souppart C, SCHOELLER J, Humbert G, MASSIAS P . Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther. 1979; 26(5):611-7. DOI: 10.1002/cpt1979265611. View

Nunn B, James F . Effect of sulphinpyrazone on human platelet aggregation, 5-hydroxytryptamine release and adhesion ex vivo: comparison with naproxen. Br J Clin Pharmacol. 1980; 9(3):239-45. PMC: 1429882. DOI: 10.1111/j.1365-2125.1980.tb04833.x. View

Burns J, Yu T, RITTERBAND A, Perel J, GUTMAN A, Brodie B . A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671. J Pharmacol Exp Ther. 1957; 119(3):418-26. View

Nenci G, Agnelli G, Berrettini M . Biphasic sulphinpyrazone-warfarin interaction. Br Med J (Clin Res Ed). 1981; 282(6273):1361-2. PMC: 1504982. DOI: 10.1136/bmj.282.6273.1361. View

Pfister B, Imhof P, WIRZ H . Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol. 1978; 13(4):263-5. DOI: 10.1007/BF00716361. View

Bern M, Cavaliere B, Lukas G . Plasma levels and effects of sulfinpyrazone in patients requiring chronic hemodialysis. J Clin Pharmacol. 1980; 20(2-3):107-16. DOI: 10.1002/j.1552-4604.1980.tb02532.x. View

Jakobsen P, Pedersen A . Two metabolites of sulphinpyrazone and their identification and determination by mass spectrometry. J Pharm Pharmacol. 1981; 33(2):89-92. DOI: 10.1111/j.2042-7158.1981.tb13717.x. View

Seegmiller J, Grayzel A . Use of the newer uricosuric agents in the management of gout. JAMA. 1960; 173:1076-80. DOI: 10.1001/jama.1960.03020280016004. View

. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med. 1980; 302(5):250-6. DOI: 10.1056/NEJM198001313020502. View

10.

Gallus A, Birkett D . Sulphinpyrazone and warfarin: a probable drug interaction. Lancet. 1980; 1(8167):535-6. DOI: 10.1016/s0140-6736(80)92783-x. View

11.

Jakobsen P, Pedersen A . Determination of sulfinpyrazone and two of its metabolites in human plasma and urine by gas chromatography and selective detection. J Chromatogr. 1979; 163(3):259-69. DOI: 10.1016/s0378-4347(00)81413-9. View

12.

Weiss M . Potentiation of coumarin effect by sulfinpyrazone. Lancet. 1979; 1(8116):609. DOI: 10.1016/s0140-6736(79)91034-1. View

13.

Davis J, JOHNS Jr L . Possible interaction of sulfinpyrazone with coumarins. N Engl J Med. 1978; 299(17):955. DOI: 10.1056/NEJM197810262991715. View

14.

Pay G, Wallis R, Zelaschi D . The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo. Haemostasis. 1981; 10(3):165-75. DOI: 10.1159/000214400. View

15.

Walter E, Staiger C, de Vries J, Zimmermann R, Weber E . Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol. 1981; 19(5):353-8. DOI: 10.1007/BF00544586. View

16.

Bailey R, Reddy J . Potentiation of warfarin action by sulphinpyrazone. Lancet. 1980; 1(8162):254. DOI: 10.1016/s0140-6736(80)90736-9. View

17.

Yue T, Dayton P, GUTMAN A . MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS. J Clin Invest. 1963; 42:1330-9. PMC: 289403. DOI: 10.1172/JCI104817. View

18.

Kersley G, COOK E, TOVEY D . Value of uricosuric agents and in particular of G. 28 315 in gout. Ann Rheum Dis. 1958; 17(3):326-33. PMC: 1007056. DOI: 10.1136/ard.17.3.326. View

19.

DUGGAN D, Hare L, Ditzler C, LEI B, Kwan K . The disposition of sulindac. Clin Pharmacol Ther. 1977; 21(3):326-35. DOI: 10.1002/cpt1977213326. View

20.

Perel J, Snell M, Chen W, Dayton P . A STUDY OF STRUCTURE--ACTIVITY RELATIONSHIPS IN REGARD TO SPECIES DIFFERENCE IN THE PHENYLBUTAZONE SERIES. Biochem Pharmacol. 1964; 13:1305-17. DOI: 10.1016/0006-2952(64)90231-x. View